Positive results for Hernexeos as a first-line treatment for HER2-mutant NSCLC

Additional clinical trial data are reinforcing the role of Hernexeos (zongertinib) as a first-line treatment option for patients with HER2-mutant non-small cell lung cancer (NSCLC). In results published April 2026 in the New England Journal of Medicine, the oral HER2-targeted therapy produced high response rates and durable disease control in previously untreated patients, building on evidence that supported its recent FDA accelerated approval.

HER2-mutant NSCLC accounts for approximately 2% to 4% of lung cancer cases and is associated with aggressive disease, poor prognosis and a high incidence of brain metastases. Unlike other oncogene-driven NSCLCs, treatment advances in this subgroup have lagged, particularly in the frontline setting, where chemotherapy has remained the standard approach with limited effectiveness.

In February 2026, FDA granted accelerated approval to Hernexeos, a HER2-selective kinase inhibitor developed by Boehringer Ingelheim Pharmaceuticals, for adults with unresectable or metastatic NSCLC with HER2 tyrosine kinase domain mutations, marking an important step toward expanding targeted options earlier in care.

In the Beamion LUNG-1 trial, first author John V. Heymach, M.D., Ph.D., of the University of Texas M.D. Anderson Cancer Center in Houston, and colleagues evaluated Hernexeos in patients with advanced or metastatic HER2-mutant NSCLC. The multicohort, phase 1a–1b study included 74 previously untreated patients who received the therapy at a dose of 120 milligrams once daily. The primary end point was objective response, with secondary end points including duration of response and progression-free survival. An exploratory cohort also assessed outcomes in patients with active brain metastases.

Among previously untreated patients, 76% achieved a confirmed objective response, consistent with the efficacy data supporting FDA approval. Responses were durable, with a median duration of 15.2 months, and median progression-free survival reached 14.4 months. These outcomes compare favorably with historical data for chemotherapy, which is associated with progression-free survival of less than seven months in this population. Notably, 64% of responders maintained their response for at least six months, and 44% for at least 12 months, according to regulatory data.

The study also provided encouraging evidence of intracranial activity. In the exploratory cohort of patients with active brain metastases, 47% experienced a confirmed intracranial response, including some who had not received prior brain-directed therapy.

Safety findings were generally consistent with prior reports. Nearly all patients experienced adverse events, but most of the events were mild. Adverse events of severity grade 3 or higher occurred in 19% of patients. The most common side effect was diarrhea, while rates of severe rash and other toxic effects typically associated with EGFR inhibition were low, reflecting the drug’s HER2 selectivity.

In their discussion, Heymach and colleagues emphasize that the high response rates and durability seen with first-line Hernexeos represent a meaningful advance for patients with HER2-mutant NSCLC, a group that has not benefited as much from targeted therapies as other molecular subtypes. The drug’s activity in patients with brain metastases is also notable, given the limited data historically available for this population.

However, the authors acknowledge important limitations, including the open-label design and lack of a comparator arm. Ongoing phase 3 trials are comparing Hernexeos with standard care to help clarify how best to use it in the treatment sequence. Researchers are also looking more closely at resistance and whether combining therapies could improve outcomes as HER2-directed options move earlier in care.

Still, as the authors conclude, Hernexeos may offer an effective and generally well-tolerated first-line alternative to chemotherapy for patients with HER2-mutant NSCLC, addressing a longstanding unmet need in this aggressive disease.